NCT04209400View on ClinicalTrials.gov

Safety and Immunogenicity of Recombinant Hepatitis B Vaccine Sci-B-Vac® Compared to Engerix-B®

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 18, 2014

Primary Completion Date

April 20, 2015

Study Completion Date

April 20, 2015

Conditions
Hepatitis B
Interventions
BIOLOGICAL

Sci-B-Vac®

Sci-B-Vac® vaccine-10 μg of HBsAg, intramuscular injection of 10 μg/ml

BIOLOGICAL

Engerix-B®

Engerix-B® vaccine-20 μg of HBsAg, intramuscular injection of 20 μg/ml

Trial Locations (1)

191167

Saint Petersburg State Budgetary Healthcare Institution, Saint Petersburg

All Listed Sponsors
lead

VBI Vaccines Inc.

INDUSTRY

NCT04209400 - Safety and Immunogenicity of Recombinant Hepatitis B Vaccine Sci-B-Vac® Compared to Engerix-B® | Biotech Hunter | Biotech Hunter